Functional analysis of Alternative Polyadenylation during neuronal differentiati...
Functional analysis of Alternative Polyadenylation during neuronal differentiation at single cell resolution
Understanding how stem cells differentiate into the myriad of cell types that compose an organism is a fundamental question in biomedical sciences. The recent development of single-cell transcriptomic techniques has already allowe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto SCAPA
Duración del proyecto: 24 meses
Fecha Inicio: 2019-03-19
Fecha Fin: 2021-03-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Understanding how stem cells differentiate into the myriad of cell types that compose an organism is a fundamental question in biomedical sciences. The recent development of single-cell transcriptomic techniques has already allowed the study of the cell composition of organs and tissues, developmental stages, and even whole adult organisms. Yet, in most cases, these studies are primarily descriptive and often provide little insight into the mechanisms regulating gene expression during cell differentiation.
Here, I propose to study the role of alternative polyadenylation (APA) and associated RNA binding proteins (RBPs) in neuronal differentiation. For this purpose, I will: (i) develop new computational tools to detect and quantify APA events from single-cell transcriptomics data; and (ii) perform a single-cell-based functional CRISPR screen. The results obtained from this study will provide an in depth analysis of the changes in gene expression and APA during neuronal differentiation at a single cell resolution and identify dozens of APA targets specifically associated with individual RBPs.
Together, this study will provide a solid molecular knowledge of the role of APA in neural differentiation, enabling the development of new personalized medicine therapies, which is in compliance with the Horizon H2020 Health demographic change and wellbeing programme.